🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in France / NCT06578390
Recruiting Not applicable

Efficacy Investigation of the Medical Device Apneal® on Smartphone for Sleep Apnea-Hypopnea Syndrome Diagnosis

NCT06578390 · tracked via the Priya Life Science France tracker
Sponsor
Mitral
Phase
Not applicable
Started
2024-03-26
Last updated
2025-09-29

Condition(s) studied

Sleep Apnea Syndromes

Investigational drug(s) / intervention(s)

Apneal device

Apneal device: Patients will wear a smartphone with the Apneal Application on their chest, while they perform polysomnography

Study summary

The goal of this clinical trial is to evaluate the effectiveness of the Apneal® app in diagnosing sleep apnea syndrome (SAS) in adults who require polysomnography (PSG) as part of routine care. The main questions it aims to answer are:

* Can Apneal® accurately classify the SAS severity into four categories (normal: AHI \< 5, mild: 5 ≤ AHI \< 15, moderate: 15 ≤ AHI \< 30, and severe: AHI ≥ 30) compared to PSG ?
* How does Apneal® perform in estimating the Apnea-Hypopnea Index (AHI), detecting sleep stages, differentiating between central and obstructive apneas, and identifying patient movements?

Participants will:

* Wear the Apneal® app-equipped smartphone and undergo PSG during a full night of sleep at home.
* Complete several questionnaires assessing sleep symptoms and experience with the Apneal® app.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Individuals, male or female, aged 18 years or older (no upper age limit). * Individuals for whom polysomnography (PSG) is indicated as part of routine care, regardless of the specific indication. * Individuals with a reported total sleep time of at least 6 hours, in accordance with AASM recommendations for PSG analysis. * Individuals affiliated with social security or benefiting from a similar system, if applicable, in accordance with local regulations. * Voluntary individuals who have provided oral and written consent after being informed by the research investigator. Exclusion Criteria: * Individuals with an active implantable medical device (e.g., electronic cardiac implant, neurophysiological electrical stimulator). * Individuals with a chest deformity that prevents proper placement of the smartphone on the chest. * Individuals with uncontrolled psychiatric disorders that prevent them from giving full consent to the study. * Individuals unable to understand or speak the official language of the research center. * Individuals currently excluded from another protocol or participating in another interventional research study. * Vulnerable persons or adults under legal protection, including pregnant or breastfeeding women, persons deprived of liberty by judicial or administrative decision, individuals hospitalized without consent, or admitted for purposes other than research (Articles L1121-5 to L1121-8 of the French Public Health Code).

Primary outcome measure(s)

Trial sites (11)

FacilityCityRegionStatus
Centre de pneumologie et sommeil Aix-en-Provence France Recruiting
Centre du sommeil d'Antony Antony France Recruiting
Pôle d'Exploration des Apnées du Sommeil de la Nouvelle Clinique Bel-Air Bordeaux France Recruiting
SomnoLab - Millénaire Montpellier France Not Yet Recruiting
Cabinet de médecine du sommeil - Cabsom Mulhouse France Recruiting
Somnology Paris France Recruiting
Institut médical du sommeil Paris France Not Yet Recruiting
Cabinet privé du Dr. Wanono Reims France Recruiting
Clinique du Renaison Roanne France Recruiting
Somnidoc Roanne France Recruiting
Centre Clinical Soyaux France Not Yet Recruiting

More Mitral trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06578390 on ClinicalTrials.gov ↗ ← All trials in France